Thymosin Alpha-1: Evidence and Legal Status 2026

Note upfront: Thymosin Alpha-1 (Tα1, brand name Zadaxin) is approved as a medicine in Italy (as an adjuvant to flu vaccination in immunocompromised people), China, and, according to the manufacturer, over 30 countries in total, outside Italy mainly for chronic hepatitis B and C. In Germany, the EU outside Italy, and the United States it is not regularly approved. This article is a purely informational, scientific overview and not a recommendation for use. Intake, dose and therapy belong exclusively in the hands of a physician.

TL;DR: Thymosin Alpha-1 is a 28-amino-acid peptide naturally produced in the thymus, available synthetically since 1977. Studies investigate how it influences T cell maturation; a bidirectional effect on the immune system is described. Approved as Zadaxin in Italy and Asia, not in most of the EU or the US. The evidence varies in strength by question: it is most extensive for hepatitis B/C and limited for sepsis and COVID-19.

What Thymosin Alpha-1 Is

Thymosin Alpha-1 (Tα1) is a 28-amino-acid peptide naturally produced in the thymus. The thymus is an organ behind the sternum that drives T lymphocyte maturation during childhood and adolescence. In adulthood, the thymus involutes and its function declines — a process linked to age-related weakening of the immune system.

In 1977, immunologist Allan Goldstein (George Washington University) first isolated and synthesized Tα1 from thymus extracts. The amino acid sequence is identical to the endogenous peptide, which distinguishes it pharmacologically from purely synthetic research peptides. The sequence reads: Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn.

Brand name Zadaxin. The pharmaceutical form is marketed by SciClone Pharmaceuticals under the name Zadaxin. In Italy it has been approved since 1993, according to its prescribing information as an adjuvant to flu vaccination in immunocompromised people; other countries added further indications. Regulatory status is the key distinction from other peptides in the biohacker scene: Tα1 has gone through approval studies, though not in every country.

For how Tα1 fits into the broader peptide landscape, see the peptides beginners guide.

Approval Status: Italy, US, EU, Asia

No other substance in this article series has such a complicated legal status. Anyone assessing Tα1 must differentiate between countries.

Italy is the regulatory outlier in the EU. Zadaxin has been approved there since 1993. According to the prescribing information published by the Italian drug authority AIFA, its only indication is as an adjuvant to flu vaccination in immunocompromised people. Italy has no approval for hepatitis.

United States. The FDA has never approved Zadaxin; any use there takes place outside the approval (off-label), and the legal status is ambiguous.

Germany and EU. Outside Italy, there is no regular approval. In Italy, Zadaxin is approved only as an adjuvant to flu vaccination in immunocompromised people; any other use would be an individual medical decision outside the approval.

Products without medicine approval. Substances offered in the EU and US as a “research chemical” are not approved medicines. Purity and identity are not assured. This article gives no information on how to obtain them.

Described Mechanism: Bidirectional Immune Modulation

According to the literature, Tα1 differs from classic immune stimulants through a bidirectional effect. The peptide is reported to bind to Toll-like receptors (mainly TLR-2 and TLR-9) on immune cells and to modulate in different directions depending on immune status.

When immune defense is weak. Tα1 is described as promoting maturation of immature T lymphocytes from the bone marrow into functional CD4 and CD8 T cells. It is reported to activate cytotoxic T cells that eliminate virus-infected and malignant cells. NK (natural killer) cell activity is reported to increase, as is production of interferon-γ and interleukin-2.

When the immune response is excessive. In extreme inflammatory situations such as sepsis or cytokine storm, Tα1 is reported to dampen the overactive immune reaction and to reduce release of proinflammatory cytokines like TNF-α and interleukin-6. This mechanism has been investigated most in sepsis and severe COVID-19.

T cell maturation. The central described effect concerns thymic function. In adults with declining thymus activity, Tα1 is reported to partially compensate for new T cell maturation. According to the literature, studies in HIV patients and after chemotherapy show this effect most clearly.

The bidirectional action explains why Tα1 is investigated across such different clinical contexts — from hepatitis to sepsis. Mechanistic descriptions do not replace proof of benefit in an individual case.

Study Landscape: What Has Been Investigated, What Remains Open

Evidence on Thymosin Alpha-1 is broad but varies widely in quality by question. A structured overview:

Hepatitis B and C (indication approved in Asia)

The most extensive data. For the combination of Tα1 and interferon in chronic hepatitis C there are randomized, placebo-controlled trials reporting an advantage over interferon alone; they underpin the Asian approvals. In chronic hepatitis B, Tα1 is investigated and used alongside standard antiviral treatments.

Sepsis

The ETASS study (Wu et al. 2013, 2015) in 361 septic patients in Chinese ICUs reported lower 28-day mortality in the Tα1 group (26 percent vs. 35 percent in controls). A meta-analysis of several studies reports a moderate effect. In the EU, Tα1 is not approved for sepsis but is mentioned in some Chinese guidelines. Study results in patient groups allow no statement about an individual case.

COVID-19

Retrospective observational data on Tα1 in COVID-19 were reported in the early phase of the pandemic. There are no randomized controlled trials, and no reliable figures for mortality or course follow from such data. Tα1 is nowhere officially approved for COVID-19, and WHO does not list it in its guidelines.

Cancer adjuvant

Small studies on melanoma, liver, and lung cancer (mostly from China) combine Tα1 with chemotherapy and report results on quality of life and, in part, survival. Evidence is not sufficient for a Western approval decision.

Long COVID, Lyme, chronic fatigue

Data thin out here. Controlled human studies are almost entirely absent. Anecdotal reports and small case series circulate in the biohacker community without methodological basis for robust claims. Any use for these questions is experimental.

Use Belongs in Medical Hands

This article deliberately gives no information on administration, amounts or duration. For approved products, the prescribing information governs how a medicine is used; what counts is always the dose set by the physician, which depends on indication, comorbidities and course. The Italian approval covers flu vaccination in immunocompromised people only, the Asian approvals other indications such as hepatitis B/C.

From pharmacology it is known that the plasma half-life of the peptide is about 2 hours, while the described biological effect via immune cell modulation lasts considerably longer. There is no basis for self-administration: preparing and using injectable products belongs in the hands of physicians or medically trained staff.

Blood Values Physicians Review

Anyone treated with immunomodulators under medical supervision needs a solid baseline and regular follow-up so that changes can be interpreted medically. The following table explains what each value measures. It is not an instruction.

More on inflammation diagnostics in the inflammation markers guide. Which values are checked and when is decided by the treating physician.

Distinction from Thymosin β4 (TB-500) and Other Thymus Peptides

A common mistake in the peptide community: Thymosin Alpha-1 and Thymosin β4 are equated because both carry thymosin in their name. That is wrong.

The common element ends with the name component thymosin, which stems from the original isolation from thymus extracts. Biologically and clinically the two peptides are different substances with different target molecules. Studies and prescribing information must therefore always be read for the specific peptide.

Contraindications and Risks

Tα1 is described as well tolerated in approval studies. Some situations are clear contraindications or call for special medical caution.

Active autoimmune disease. Rheumatoid arthritis, lupus, multiple sclerosis, active Hashimoto flares. Immune stimulation can intensify autoimmune inflammation. Whether and to what extent an autoimmune screen (ANA, rheumatoid factor, specific antibodies as needed) is required is decided by the physician.

After organ transplantation. Tα1 is contraindicated here. Transplant patients need permanent immunosuppression to prevent rejection. Immune stimulation works in the opposite direction and may endanger the graft.

Pregnancy and breastfeeding. Insufficient data. Use is not advisable without a compelling medical indication.

Allergic reactions. Very rare but possible. With known hypersensitivity to ingredients of the product, medical advice should be sought.

Injection risks. Abscesses and infections are possible with non-sterile use. This is not specific to Tα1 — it applies to any injection.

Quality risks with unregulated products. Without a medicine approval and the quality control that comes with it, purity and identity of a product are not assured. For quality questions around unregulated peptides, see also the BPC-157 analysis.

Context: Where Research Focuses

Thymosin Alpha-1 is one of the few peptides in biohacker discussion with an actual regulatory anchor — Italian and Asian approval. That distinguishes it from BPC-157, Epithalon, or Selank, which are not approved as medicines anywhere.

According to the studies cited above, Tα1 has mainly been investigated in hepatitis B and C, sepsis, COVID-19 and as an adjuvant in cancer research; the evidence is limited to inconsistent. Outside the approvals mentioned, Tα1 is not approved as a medicine in Germany.

For everything else — anti-aging, performance enhancement, nonspecific fatigue — evidence is lacking. Whether any use comes into question at all is decided exclusively by the treating physician; this article makes no recommendation.

For a structured baseline of your own lab values that can be discussed with a physician, see the biomarker baseline checklist. The peptides beginners guide places Tα1 in the broader peptide landscape.

Conclusion: Approved in Italy, Limited Evidence

Thymosin Alpha-1 is a well-researched peptide with approvals in Italy (as a vaccine adjuvant), China (hepatitis B) and, according to the manufacturer, over 30 countries in total, each for clearly defined indications. The described bidirectional immune modulation makes it scientifically interesting — most data exist for hepatitis, while for sepsis, COVID-19 and cancer adjuvant the evidence does not yet support robust statements.

Three takeaways:

1. Regulatory reality. Not regularly approved in most of the EU or in the US. In Italy the approval covers only an adjuvant to flu vaccination in immunocompromised people, not hepatitis.
2. Difference from TB-500. Thymosin Alpha-1 and Thymosin β4 are different peptides. Name similarity is misleading.
3. Medical clarification. Intake, dose and therapy belong in medical hands; lab values such as complete blood count, lymphocyte subsets, liver and kidney values help interpret findings.

For digital tracking of blood values, the Lab2go features provide the right tools. The pricing overview shows tier options for detailed biomarker tracking.

This article is purely informational, does not replace medical advice and contains no recommendation for use. Thymosin Alpha-1 is not regularly approved as a medicine in Germany, most of the EU, or the US. Intake, dose and therapy should be clarified with a physician — self-medication with unapproved peptides carries health and legal risks.